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Abstract 
Efficacious anticancer therapies for targeting plasma membrane receptors with antibody based therapeutics are 
often contingent on sufficient endocytic delivery of receptor and conjugate to lysosomes. This results in 
downregulation of receptor activity and, in the case of antibody-drug conjugates (ADCs), intracellular release 
of a drug payload. The oncogenic receptor HER2 is a priority therapeutic target in breast cancer. Known as an 
“endocytosis resistant” receptor, HER2 thwarts the receptor downregulating efficiency of the frontline 
treatment trastuzumab and reduces the potential of trastuzumab-based therapies such as 
trastuzumab-emtansine. We previously demonstrated that strategically inducing trastuzumab and HER2 
crosslinking in breast cancer cells promoted endocytosis and lysosomal delivery of the HER2-trastuzumab 
complex, stimulating downregulation of the receptor. Here we reveal that HER3, but not EGFR, is also 
concomitantly downregulated with HER2 after crosslinking. This is accompanied by strong activation of 
MEK/ERK pathway that we show does not directly contribute to HER2/trastuzumab endocytosis. We show 
that crosslinking induced trastuzumab endocytosis occurs via clathrin-dependent and independent pathways 
and is an actin-dependent process. Detailed ultrastructural studies of the plasma membrane highlight 
crosslinking-specific remodelling of microvilli and induction of extensive ruffling. Investigations in a cell model of 
acquired trastuzumab resistance demonstrate, for the first time, that they are refractory to crosslinking 
induced HER2 endocytosis and downregulation. This implicates further arrest of HER2 internalisation in 
developing trastuzumab resistance. Overall our findings highlight the potential of receptor crosslinking as a 
therapeutic strategy for cancer while exposing the ability of cancer cells to develop resistance via endocytic 
mechanisms. 
Key words: HER2, crosslinking, endocytosis  
Introduction 
Human epidermal growth factor receptor 2 
(HER2) belongs to the ErbB family of receptor 
tyrosine kinases and is a critical therapeutic target due 
to its role in the development and progression of a 
range of cancers (1). Recent clinical data indicate that 
it is overexpressed in 15-20% of breast cancers (2, 3) 
and it has long been associated with more aggressive 
mammary tumours and poorer patient prognosis (4). 
HER2 promotes cancer cell proliferation, invasion, 
metastasis and angiogenesis via activation of the 
PI3K/Akt and Ras/Raf/MEK/ERK signalling 
cascades (5). Attenuation of oncogenic signalling 
pathways is regulated by endocytosis (6) but HER2 
has been shown to be confined to plasma membrane 
protrusions and is termed an 'endocytosis-resistant' 
receptor (6, 7). Aspects regarding its endocytosis are 
controversial: there is evidence that HER2 expression 
impairs clathrin coated pit formation at the plasma 
membrane (8), that the receptor constitutively recycles 
(9, 10) and that the HER2 cytoplasmic domain 
contains a membrane retention signal (11). Recycling 
pathways also maintain the plasma membrane pool of 
HER2, enabling repeated stimulation and prolonged 
signalling. HER2 is the preferred dimerisation partner 
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of all ErbB family members and upon hetero-
dimerisation, it confers downregulation resistance to 
partner receptors. Thus, endocytosis-deficient, HER2- 
containing heterodimers elicit prolonged downstream 
signalling responses (12, 13). 
HER2 has been therapeutically targeted by the 
monoclonal antibody trastuzumab (Tz). Despite being 
an approved treatment for almost two decades, the 
mechanisms underlying Tz activity and resistance are 
complex and only partially understood. To varying, 
often limited degrees, Tz has been reported to induce 
HER2 endocytosis and downregulation (14). It has 
demonstrated activity against HER2-overexpressing 
breast cancers but resistance and relapse represent 
significant problems (15). Recently a number of 
strategies have been published to address this, 
directly or indirectly based on the mechanism of 
receptor crosslinking. We, and others, have published 
that inducing crosslinking/clustering of HER2 with 
targeted antibodies leads to enhanced lysosomal 
delivery and degradation (16-21). Other therapeutic 
strategies exploiting the endocytosis potentiating 
effect of receptor clustering include dendrimers, 
aptamers and nanoparticles (22-24). 
Here we show, compared with Tz alone, induc-
tion of Tz crosslinking in HER2-overexpressing breast 
cancer cells promotes extensive plasma membrane 
remodelling, driving internalisation and delivery of 
antibody:receptor complexes to lysosomes. HER2 
degradation is accompanied by activation of MEK 
and ERK with concomitant downregulation of HER3, 
but not EGFR. The crosslinking approach, however, is 
shown to only be effective in Tz-sensitive cell lines 
and not in a model of acquired Tz-resistance. This has 
significant implications for existing and future 
antibody-based cancer therapies that seek to exploit 
receptor-crosslinking for enhanced lysosomal 
delivery and degradation.  
Materials and Methods 
Cell lines and culture 
SKBR3 (ER-, HER2+), BT474 (ER+, HER2+) and 
BT474 clone 5 (ER+, HER2+, Tz resistant) and MCF7 
(ER+, HER2-) human breast cancer cells were obtained 
directly from LCG Standards, UK supplier of 
authenticated American Type Culture Collection 
(ATCC) cells. The ATCC and RRID codes for the cell 
lines are as follows: SKBR3 (ATCC: HTB-30, RRID: 
CVCL_0033), BT474 (ATCC: HTB-20, RRID: CVCL_ 
0179), BT474 clone 5 (ATCC: CRL-3247, RRID: 
CVCL_AQ07) and MCF-7 (ATCC: HTB-22, RRID: 
CVCL_0031). All cells were cultured at 37°C in a 5% 
CO2 humidified atmosphere in complete medium: 
Dulbecco's Modified Eagle Medium (DMEM, Gibco, 
Fisher, UK) containing phenol red and supplemented 
with 10% v/v foetal bovine serum (FBS, Gibco, Fisher, 
UK), referred to as complete medium. Cell lines were 
used to 28 passages (maximum) and were subject to 
quarterly mycoplasma testing (MP0035, Sigma). 
Generation and characterisation of 
fluorescent, biotinylated trastuzumab 
construct 
Tz solution (containing: 21mg/ml Tz, L-histidine 
HCl, L-histidine, α,α-trehalose dehydrate, and 
polysorbate) was donated by Velindre Cancer Centre 
(Cardiff, UK). For labelling, as previously published 
(16), this clinical formulation (1.5 mL, 32 mg Tz) was 
sequentially buffer-exchanged into phosphate 
buffered saline (PBS) pH 7.4, via two 10 mL Zeba Spin 
desalting columns (Fisher Scientific). Of the 1.7 mL 
eluted from the column, 1.5 mL of Tz (30 mg) was 
added directly to 1 mg NHS-Alexa647 (Life Technolo-
gies) and 400 µl of 1 mg/mL NHS-biotin (Fisher 
Scientific) PBS (pH 7.4). Conjugation reactions were 
allowed to proceed for 1 hr at room temperature. 
Resulting Tz-construct was purified using two 10 mL 
Zeba Spin desalting columns (1 mL/column) in PBS 
(pH 7.4). This was then sterile filtered (0.2 µm), 
aliquoted into Eppendorf tubes, snap-frozen and 
stored at −20 °C. 
UV-visible absorbance spectrum of the 
Tz-construct was obtained using a Jasco V-650 UV-Vis 
spectrophotometer. Biotin concentrations were 
calculated using an HABA Biotin Quantification Kit 
according to manufacturer’s instructions (Pierce, UK) 
(16). 
Antibody-receptor crosslinking targeting 
HER2 
Cells were seeded into 6-well plates (for Western 
blotting) or 35 mm glass bottomed imaging dishes (for 
confocal microscopy) to obtain 70-80% confluency on 
the day of experimentation (~60 hr post-seeding). For 
crosslinking: cells were incubated for 30 min at 37 °C, 
5% CO2 with 50 nM Tz-construct in 500 µL complete 
imaging medium (CIM: phenol-red free DMEM 
supplemented with 10% FBS). Cells were washed 
three times with sterile PBS (pH 7.4) and then 
incubated with 500 µl of 1 μg/mL streptavidin (SA) in 
CIM or CIM only for 1 hr. The cells were then washed 
3x in PBS before being incubated in complete medium 
for 6 hr (standard crosslinking protocol) or as 
indicated in the text.  
siRNA depletion of endocytic proteins 
siRNA sequences: Dharmacon ON-TARGET plus 
SMARTpool siRNAs were obtained from GE Health-
care targeting AP2M1 (L-008170-00-0005), CAV-1 
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(L-003467-00-0005) and FLOT-1 (L-010636-00-0005). 
Non-targeting siRNA control, GFP (5’-GGCUACGUC 
CAGGAGCGCAdTdT-3’) was synthesised by MWG. 
SKBR3 cells (300,000) were seeded in 35 mm 
glass- bottomed imaging dishes (MatTek) and 
incubated for 24 hr in complete medium. The 
transfection mixture was prepared the following day 
by mixing: transfection reagent 2.4 μL Dharmafect1 
(Fisher, UK) with 237.6 μL OptiMEM (Fisher, UK) and 
incubating at room temperature for 5 min. Meanwhile 
12 μL of 5 μM siRNA was mixed with 228 μL 
OptiMEM. Diluted Dharmafect1 was then mixed with 
the diluted siRNA and incubated at room 
temperature for 30 min. The cell medium (in the 
6-well plate) was replaced with 1920 μL of compete 
medium. The transfection mixture (480 μL) was then 
added to each well, giving a 25 nM final siRNA 
concentration. The cells were incubated in their 
transfection medium at 37°C, 5% CO2 for 48 hr before 
further experimentation. 
Western blotting 
Cell lysates were collected on ice from 6-well 
plates by scraping with NP40 lysis buffer 
supplemented with protease and phosphatase 
inhibitors (Roche). Denatured/reduced samples (18 
μg total protein/ sample) were separated by 
SDS-PAGE (Bio-Rad) and were transferred to 
Polyvinylidene fluoride (PVDF) membranes. Sample 
membranes were blocked in 5% milk in PBST (0.025% 
Tween20) for 1 hr at room temperature then incubated 
overnight at 4 °C with primary antibodies diluted in 
2% milk in PBST (see Supplementary Table 1). 
Membranes were washed 3x 5 min in PBST prior to 1 
hr incubation with species specific secondary 
antibodies (all from Peirce) diluted 1:1000 in 2% milk 
in PBST. An exception to this was for anti-tubulin 
HRP conjugate, for which the signal was detected 
after washing. Following secondary antibody 
incubation, membranes were washed 3x 5 min in 
PBST ready for signal detection by enhanced 
chemiluminescence (ECL, Femto, Fisher). Membranes 
were imaged using a ChemiDoc XRS+ (Bio-Rad, 
Hemel Hempstead, UK) running ImageLab with 
images obtained before saturation is reached. 
Densitometry was performed with Fiji software and 
normalised to loading control bands for relevant 
total/housekeeping proteins. 
Antibody stripping for membrane reprobing 
Where required e.g. for comparing levels of 
activated and total protein, membranes were stripped 
and re-probed as follows: 2x 5 min washes in PBS 
followed by 2x 5 min washes in dH2O, they were 
stripped for 10 min in 0.2 M NaOH, washed twice 2x 5 
min in dH20 and washed a final 2x 5 min in PBS. 
Stripped membranes were then used for immuno-
blotting, following the procedure from the blocking 
step onwards. 
Dextran labelling of lysosomes for 
co-localisation analysis 
Lysosome co-localisation analysis was 
performed as previously published (16). Briefly: cells 
were pulsed for 16 hr with the fluid-phase endocytic 
probe Dextran-555 (D34679, Molecular Probes) (25) 
diluted to 200 μg/mL in 500 µL complete medium. 
This was subsequently chased over the duration of the 
crosslinking experiment with dextran-free complete 
imaging medium.  
Actin disruption and visualisation 
SKBR3 cells (120,000) were seeded onto glass 
coverslips and cultured at 37°C, 5% CO2 for 48 hr. Tz 
uptake experiments (+/- crosslinking) were then 
performed in the continuous presence of DMSO 
diluent control or 5 µM CytD to disrupt the actin 
cytoskeleton (26). At the end of the uptake experiment 
(total CytD/vehicle exposure time = 7.5 hr) cells were 
fixed in 3% PFA for 15 min, washed 3x with PBS then 
permeabilised in 0.2% Triton X-100 and washed a 
further 3x in PBS. To visualise the filamentous actin 
the cells were incubated with 1.0 µg/ml Rhodamine- 
Phalloidin in PBS for 15 min at room temperature. The 
cells were finally washed 3x with PBS then dipped 
once into PBS, once into distilled water and coverslips 
were then mounted in 12 µL DAKO oil on glass 
microscope slides and imaged by confocal 
microscopy. 
MEK/ERK inhibition  
SKBR3 cells (300,000) were seeded in 35 mm 
glass-bottomed imaging dishes (MatTek) and 
cultured at 37°C, 5% CO2 for 48 hr. Tz uptake (+/- 
crosslinking) was then performed in the continuous 
presence of DMSO diluent control or 20 nM 
trametinib (total trametinib/vehicle exposure time = 
7.5 hr). Cells were then imaged live by confocal 
microscopy. 
Live-cell imaging confocal microscopy 
Cells were imaged live with a Leica SP5 confocal 
laser-scanning microscope equipped with a 37°C 
heated stage CO2 perfused humidified chamber 
(Ibidi), 488 nm Argon, 543/633 nm Helium-Neon 
lasers and a 63× 1.4 numerical aperture (NA) oil 
immersion objective. Gain and offset settings were 
optimised for the untreated/control cells at the start 
of each independent experiment and were maintained 
for the duration. Images were captured with the 
sequential scanning mode using a line average of 2. 
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Scanning electron microscopy (SEM)  
SKBR3 cells (125,000) were seeded onto glass 
coverslips in a 12-well plate. After 24 hr incubation 
(37°C, 5% CO2) the cells were incubated for 30 min 
with 50 nM Tz-bi-647 or diluent control in imaging 
medium. They were then washed 3x in PBS and 
incubated for 10 min with either 1 μg/mL SA (or 
diluent control) in imaging medium. At room 
temperature: the cells were washed 3x in PBS, fixed in 
2% glutaraldehyde for 30 min, washed a further 3x in 
PBS and post-fixed in 1% Osmium tetroxide in PBS for 
30 min. The cells were washed another 3x in PBS then 
dehydrated through sequential, 10 min incubations 
with increasing concentrations of ethanol from 
50%-100%. Dehydrated cells were then transferred 
from ethanol to hexamethyldisilazane (HMDS) by 10 
min washes in Ethanol:HMDS solutions starting at a 
ratio of 50:50 and repeated with 25:75 10:90 and 
ending on three 10 min incubations in 100% HDMS. 
Excess HMDS was aspirated and the cells were 
allowed air dry overnight in a fume cupboard. 
Coverslips were mounted onto stage inserts and were 
sputter-coated with gold-palladium (BIO-RAD 
SC-500 for sputter coating with argon gas for plasma) 
before imaging by SEM (Zeiss Sigma HD Field 
Emission Gun Analytical SEM). For imaging the 
accelerating voltage (EHT) was 5.00 kV with probe 
current of <100 pA and a working distance of 5 mm. 
Images showing the SKBR3 cell surface had a 
magnification of 10.00 K X and 30.00 K X.  
Cell viability 
Cell viability at 72 hr post-crosslinking treatment 
was assessed by CellTiter-Blue® assay (#G8080, 
Promega) according to manufacturer's instructions. 
Briefly, cells were seeded (3,000 per well) into black 
96-well plates and incubated at 37°C, 5% CO2 
overnight. The following day the crosslinking 
protocol was carried out and cells were returned to 
the incubator for 67 hr after the final medium change. 
At 68 hr post-crosslinking, 20 μL of CellTiter-Blue 
reagent was added to each well and the plates were 
returned to the incubator for 4 hr. Viable cell- 
generated fluorescence was quantified with a Fluostar 
Optima fluorescent plate reader (544Ex/590Em). 
Statistical methods 
For qualitative experiments e.g. microscopy data 
(Fig. 2E, 3A, 4, 5A, 6A) at least two independent 
experiments were carried out. For quantitative 
experiments e.g. all immunoblotting and co-localisa-
tion analysis, three independent experiments were 
performed. Where duplicates were obtained in 
immunoblotting data, separate means were calculated 
for each independent experiment. Quantitative data 
are presented as the average of the independent 
means ± standard error of the mean (SE). One-way 
ANOVA tests were performed to analyse each dataset 
across the three independent experiments. Where 
statistically significant differences were obtained 
(P<0.05) Tukey Post-hoc testing was performed to 
determine significant mean differences between 
groups. In the main body of text only Tukey p-values 
are reported, for full ANOVA statistic outputs see 
Supplementary Figure S6.  
Results 
Tz:HER2 crosslinking induces concomitant 
downregulation of HER3 but not EGFR 
We have previously shown that SA induced 
crosslinking of biotinylated Tz can enhance endocytic 
delivery and degradation of HER2 in lysosomes (16). 
We used our previously published methods to label 
Tz with biotin and Alexa647, producing a fluorescent 
antibody amenable to crosslinking. Construct charac-
terisation by UV spectral analysis and biotin quantifi-
cation assay indicated means of 3.9 fluorophores and 
6.0 biotin moieties per antibody (Supplementary 
Figure S1A). For functional characterisation, the 
Tz-construct was applied to HER2-overexpressing 
(SKBR3 and BT474) cells and HER2-/low (MCF-7) cells 
followed by SA to induce crosslinking (or diluent 
control). Cells were imaged live by confocal 
microscopy at 1 and 7 hr post- crosslinking (Figure 
S1B). At 1 hr, bright labelling was detected at the 
plasma membrane of the SKBR3 and BT474 
(HER2-overexpressing) cells with minimal evidence 
of binding in the MCF-7 (HER2-/low) cells; indicating 
specificity for HER2. At 7 hr, SA-induced crosslinking 
lead to greater Tz internalisation in SKBR3 and BT474 
cells: as demonstrated by reduced plasma membrane 
labelling and increased vesicular fluorescence. No 
differences +/- crosslinking were detected in the 
MCF-7 cells and collectively the results indicated the 
construct behaved as previously described (16).  
HER2 readily dimerises with other ErbB 
receptors, forming heterodimers at the cell membrane 
with ligand-bound partners. We therefore sought to 
determine whether induction of Tz:HER2 
crosslinking, that we have shown to potentiate HER2 
degradation (16), could also affect the receptor’s 
binding partners. For this we performed crosslinking 
in SKBR3 and BT474 cells and (at 7 hr) examined 
HER3 and EGFR levels. Uncrosslinked Tz in SKBR3 
cells produced a small but statistically significant 
reduction in HER3 levels compared to control with no 
change in EGFR levels (Figure 1). In BT474 cells 
uncrosslinked Tz did not significantly alter levels of 
either receptor. In both cell lines Tz-crosslinking 
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induced consistent, substantial and significant 
reductions in HER3 compared with controls while 
EGFR levels were not significantly altered. HER3 and 
EGFR were shown to co-precipitate with HER2 in 
both SKBR3 and BT474 cell lines (Supplementary 
Figure S2) indicating that both proteins share an 
association with HER2 in these cells. 
Tz-HER2 crosslinking alters HER2’s activation 
and downstream signalling profile  
Activated HER2 heterodimers stimulate onco-
genic signalling via the PI3K/Akt and Ras/Raf/ 
MEK/ERK pathways. Tz, as a synthetic HER2 ligand, 
affects receptor activation and downstream signalling 
differently depending on dose, duration of exposure 
and therapeutic sensitivity/resistance (27-29). We 
therefore aimed to determine whether crosslinking 
altered the activation profile of HER2 at selected 
phosphorylation residues and/or if the activities of 
critical downstream signalling nodes Akt and ERK 
were affected. From Western blots, levels of activated 
protein were calculated relative to total levels of the 
same protein (e.g. P-Akt to total Akt) except total 
HER2 which was normalised to total ERK 
(housekeeping/loading control). As we reported 
previously (16) compared with Tz alone, crosslinking 
(Tz+SA) caused greater downregulation of HER2 
from untreated control levels in both SKBR3 and 
BT474 cells (Figure 2). Levels of Tyr-877 P-HER2 were 
reduced in proportion to HER2 for both BT474 and 
 
 
Figure 1. Crosslinking-specific reduction in HER3 in HER2+ breast cancer cells is induced by Tz:HER2-crosslinking. SKBR3 and BT474 cells were either 
untreated (control) or incubated with Tz diluent control 30 min followed by SA alone for 1 hr, Tz alone for 30 min (+ 1 hr SA diluent control), or Tz for 30 min followed by SA 
for 1 hr (Tz+SA). Following treatments the cells were chased in CIM for 6 hr. Cell lysates were collected from three independent experiments A) Western blotting was 
performed for HER3, EGFR and β-tubulin (representative blot shown) and b) band intensities were quantified using ImageJ software. Mean from 3 independent experiments shown, error 
bars depict SE, *p≤0.05, **p≤0.01, ****p≤0.0001. The data revealed that HER3, but not EGFR, was specifically reduced by HER2 targeted crosslinking. 
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SKBR3 cells. This was also true of Tyr-1248 P-HER2 in 
the BT474 cell line. However, in SKBR3 cells there was 
a significantly greater reduction in Tyr-1248 P-HER2 
relative to total HER2 induced by crosslinked Tz 
compared with Tz alone (Figure 2B). Akt activation 
was generally reduced by Tz and Tz+SA, as has been 
reported for Tz previously (30), however, there was 
no difference in the reduction with or without 
crosslinking. Tz alone did not significantly induce 
ERK activation above baseline, however, there was a 
marked, crosslinking-specific increase in ERK 
activation in both cell lines. 
SKBR3 cells were assessed for ERK activation 
and total HER2 levels at earlier time points (1 and 3 
hr) post-crosslinking (Supplementary Figure S3A and 
B). The data demonstrate that initially (1 hr) ERK was 
strongly phosphorylated following treatment with Tz 
± crosslinking. At both time points ERK appeared to 
be more activated in Tz+SA treated cells compared 
with Tz alone but differences did not reach 
significance. After 1 hr, total HER2 levels were not 
significantly different with and without Tz and/or 
crosslinking but at 3 hr there was an indication that 
Tz+SA treatment had begun to reduce the receptor 
levels. The combined data from Figures 2 and S2 
suggest that in a 7 hr period crosslinking gradually 
reduces the levels of HER2 while amplifying/ 
prolonging Tz-induced ERK activation. 
Various pathways can stimulate ERK activation 
and we analysed the phosphorylation status of the 
upstream ERK kinase (MEK) in response to 
crosslinking. Data from SKBR3 and BT474 lysates 
suggested that a proportion of the ERK phosphoryla-
tion seen in Figure 2 was a result of increased MEK 
activity (Supplementary Figure S3 C-D). We sought to 
determine whether this MEK/ERK activity was a 
consequence of, or a requirement for, crosslinking- 
enhanced Tz:HER2 endocytic degradation. For this 
we conducted antibody uptake and receptor 
downregulation experiments in the presence and 
absence of the MEK inhibitor trametinib. Figure 2C 
demonstrates efficient abolition of ERK activity in 
trametinib treated cells and coupled with Figure 2D 
indicates that this inhibition did not significantly alter 
the HER2 downregulating effect of crosslinking. This 
is supported by confocal microscopy data (Figure 2E) 
demonstrating that the inhibition of MEK/ERK did 
not affect the ability of crosslinking to increase Tz 
internalisation. Reduced membrane labelling and 
increased vesicular accumulation of Tz in the 
crosslinking treated cells occurred with and without 
trametinib.  
Tz:HER2 crosslinking induced endocytosis 
occurs by clathrin dependent and independent 
endocytic pathways 
Clathrin dependent and independent 
mechanisms have been implicated in the endocytosis 
of HER2 and Tz (8, 31, 32) and in crosslinking-based 
approaches for enhanced receptor internalisation (21). 
To investigate the contribution of specific pathways to 
crosslinking induced Tz:HER2 endocytosis we used 
siRNA to deplete critical endocytic targets (33). 
SKBR3 cells were transfected with control siRNA or 
those targeting AP2M1 to impair clathrin-dependent 
endocytosis or caveolin-1 (CAV1) or flotillin-1 
(FLOT1) to inhibit selected clathrin-independent 
pathways. After 48 hr transfection, cells were 
incubated with Tz for 30 min and imaged, then 
incubated for 7 hr with either diluent control or SA 
and imaged (Figure 3A). SA-induced crosslinking 
promoted HER2 internalisation compared with 
diluent controls under all conditions, however, in 
AP2M1, CAV1 and FLOT1 depleted cells 
crosslinking-induced internalisation was reduced 
compared with controls. This was demonstrated by 
increased Tz plasma membrane retention at and 
reduced vesicular accumulation in the crosslinking 
treated, endocytosis compromised cell models 
compared with control crosslinking-treated cells. 
Lysates made from these cells after imaging were 
used to confirmed depletion of target proteins by 
Western blotting (Figure 3B). 
Tz-HER2 crosslinking induces remodelling of 
the plasma membrane 
To investigate the cellular processes preceding 
endocytosis in more detail, we examined the 
structure/topography of the plasma membrane at an 
early time point post-crosslinking. For this we 
prepared samples of control, Tz treated and Tz+SA 
treated SKBR3 cells for SEM, fixing cells after 30 min 
of Tz addition and 10 min +/- SA crosslinking. 
Untreated cells were also examined as controls and 
micrographs display the microvilli that typically 
cover the surface of SKBR3 cells (Figure 4). This is a 
feature that has been previously reported for 
HER2-overexpressing cells: HER2 has both been 
shown to be retained in these microvilli (7) and to 
induce their formation (34). The application of Tz 
alone induced some remodelling at the plasma 
membrane typified by flattening and broadening of 
the microvilli, this phenotype was however greatly 
enhanced in the SA-crosslinked cells. A secondary 
phenotype was also observed following crosslinking 
in the form of extensive plasma membrane ruffling 
located on one or more regions of the cells. 
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Figure 2. Crosslinking-specific alterations in HER2 levels, activation and downstream signalling are detected in HER2+ breast cancer cells following 
induction of Tz:HER2-crosslinking and the enhanced ERK activation is a consequence not a driver of crosslinking enhanced Tz:HER2 endocytosis. SKBR3 
cells and BT474 cells were either untreated (control) or incubated with Tz diluent control 30 min followed by SA alone for 1 hr, Tz alone for 30 min (+ 1 hr SA diluent control), 
or Tz for 30 min followed by SA for 1 hr (Tz+SA) then chased for a further 6 hr in CIM. Cell lysates were collected from three independent experiments, representative blots 
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are shown. A) Western blotting was performed for HER2, pHER2 (Tyr-1248), P-AKT (Ser-473), total AKT, P-ERK (Thr-202/Tyr-204) and total ERK. B) Band intensities were 
quantified using ImageJ software. Mean from 3 independent experiments is shown, error bars represent SE, *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001. The data demonstrate 
that crosslinking reduced levels of HER2 and induced activation of ERK in both cell lines and reduced the proportion of HER2 phosphorylated at Tyr-1248 
in SKBR3 cells. C) SKBR3 cells were, in the continuous presence of 20 nM trametinib or diluent control, either untreated (control) or incubated with Tz diluent control 30 min 
followed by SA alone for 1 hr, Tz alone for 30 min (+ 1 hr SA diluent control), or Tz for 30 min followed by SA for 1 hr (Tz+SA) followed by a 6 hr chase in CIM. D) Band 
intensities were quantified using ImageJ software. Mean from 3 independent experiments is shown, error bars represent SE, *p≤0.05. Data show that there was no significant 
difference in crosslinking-enhanced downregulation of HER2 in the presence of MEK/ERK inhibition. E) Confocal microscopy analysis of ERK activation 
dependency of crosslinked Tz:HER2 internalisation. Cells were incubated, in the presence of 20 nM trametinib or diluent control, with Tz for 30 min and imaged (left column). 
Cells were then incubated for 1 hr with either diluent control (middle column) or SA (right column). Following treatments cells were chased in complete imaging medium for 6 
hr and imaged. Scale bar = 50 µm. Data demonstrate that inhibiting MEK/ERK did not significantly alter crosslinking-enhanced internalisation of Tz. 
 
Figure 3. Enhanced uptake of Tz:HER2 induced by crosslinking is reduced by inhibiting clathrin dependent and independent endocytosis. A) Confocal 
microscopy analysis of endocytic pathways governing internalisation of Tz-HER2 membrane clusters. SKBR3 cells were transfected with GFP (control) siRNA or sequences 
targeting AP2M1, caveolin-1 (CAV1) or flotillin-1 (FLOT1) to impair clathrin-dependent and -independent endocytic pathways respectively. Transfected cells (48 hr) were 
incubated with Tz for 30 min and imaged (left column). Cells were then incubated for 1 hr with either diluent control (middle column) or streptavidin (SA, right column). 
Following treatments cells were chased in complete imaging medium for 6 hr and imaged. Scale bar = 50 µm, red arrows depict increased membrane retention of Tz. Data show 
that SA induced crosslinking promoted HER2 internalisation compared with diluent controls under all conditions, however, in AP2M1, CAV1 and FLOT1 depleted cells 
clustering-induced internalisation was significantly reduced compared with controls. B) Western blotting control data using lysates of the cells imaged in (A). Immunoblots show 
successful depletion of AP2M1, CAV1 and FLOT1. 
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Figure 4. Crosslinking induces remodelling at the plasma membrane of SKBR3 cells. Cells were either untreated (control) or incubated with Tz alone for 30 min (+ 
10 min SA diluent control), or Tz for 30 min followed by SA for 10 min (Tz+SA). Cells were fixed, dehydrated, sputter coated and imaged by SEM. Two cell phenotypes were 
observed in response to crosslinking (bottom row): 1) broadened/flattened microvilli and 2) plasma membrane ruffles indicative of macropinocytosis. Scale bar = 1 µm. 
 
Tz:HER2 endocytosis, with and without 
crosslinking, is actin-dependent 
Actin is a critical regulator of endocytosis, 
plasma membrane organisation and structure (26, 35). 
Other HER2-crosslinking based approaches have 
suggested a role for actin/macropinocytosis in HER2 
internalisation (21) and this combined with our SEM 
data led us to examine the actin-dependency of 
crosslinking. For this we conducted control versus Tz 
alone versus Tz+SA experiments in the presence and 
absence of cytochalasin D (CytD). CytD is an actin 
filament disrupting agent and widely-used inhibitor 
of macropinocytosis (26). Confocal microscopy data in 
Figure 5A depicts SKBR3 cells incubated with Tz 
alone or Tz+SA in the continuous presence of CytD or 
DMSO diluent control. Crosslinking, as expected, 
increased vesicular accumulation and reduced plasma 
membrane localisation of Tz in control cells. 
However, in the presence of CytD this effect was 
dramatically reduced: with or without SA 
crosslinking Tz was largely confined to the plasma 
membrane. These findings were supported by 
Western blotting data examining levels of HER2 and 
P-ERK (Figure 5B). CytD inhibited crosslinking- 
induced downregulation of HER2 and reduced recep-
tor levels. Surprisingly, ERK activation was reduced 
by CytD treatment though the trend of Tz induced 
activation and enhancement by crosslinking was still 
evident despite being reduced in magnitude. Control 
data in Supplementary Figure S4A demonstrates via 
rhodamine-phalloidin labelling that actin is disrupted 
under these experimental conditions. 
Crosslinking does not enhance Tz-HER2 
endocytosis and degradation in a cell model of 
acquired Tz resistance 
Therapeutic resistance represents a significant 
limitation of Tz treatment and a number of clustering 
based approaches are being developed to address this 
clinical problem (18, 21, 36). We therefore tested our 
crosslinking strategy in the BT474 clone 5 model of 
acquired Tz resistance. This cell line has been shown 
to express surface levels of HER2 comparable to the 
parental BT474 cells (37) and we were able to confirm 
that our Tz-construct could still bind to the resistant 
clone (Supplementary Figure S4B). We initially 
investigated whether crosslinking would enhance 
endocytic uptake and lysosomal delivery of Tz:HER2 
as we demonstrate here and previously in the parental 
BT474 line (16). For this we pre-labelled late 
endolysosomes with dextran prior to crosslinking and 
subsequent co-localisation analysis by confocal 
microscopy. To our surprise, data in Figure 6A 
demonstrate that there was little colocalisation 
between Tz and the late endolysosomes with or 
without crosslinking in the Tz-resistant cell line. We 
then examined the levels of HER2 and ERK activation 
status in response to Tz and crosslinking treatments 
(Figure 6B-C). In contrast to our crosslinking findings 
in Tz-sensitive cells (Figure 2) we found that in the 
resistant clone there were no significant differences in 
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HER2 levels in response to Tz or crosslinking 
treatment. ERK was phosphorylated in response to Tz 
alone and to Tz+SA, however there was no 
enhancement of ERK activation by crosslinking. 
Cell TiterBlue experiments performed at 72 hr 
post-crosslinking in the BT474 clone 5, BT474 and 
SKBR3 cells demonstrated no significant effects of the 
30 min Tz alone treatment or of Tz followed by SA 
(Supplementary Figure S5A). This was unsurprising 
as we have previously showed, and again 
demonstrate in Supplementary Figure S5B that HER2 
levels recover within 48 hr of Tz crosslinking 
challenge (16). 
Discussion 
Elucidating the fundamental molecular mechan-
isms governing antibody receptor crosslinking in 
cancer cells may improve existing therapeutic 
strategies, guide the development of future 
approaches and provide insight into overcoming 
treatment resistance. Here we sought to characterise 
the mechanisms involved in a crosslinking strategy 
 
 
Figure 5. Tz internalisation and crosslinking-enhanced downregulation of HER2 is actin dependent. A) Confocal microscopy analysis of actin dependency of 
crosslinked Tz:HER2 internalisation. SKBR3 cells were incubated, in the presence of 5 µM CytD or diluent control, with Tz for 30 min. They were then incubated for 1 hr with 
either diluent control (middle column) or SA (right column) ± CytD. Following treatments cells were chased in complete imaging medium (containing CytD or diluent control) 
for 6 hr and imaged. Scale bar = 50 µm. Data demonstrate that disruption of filamentous actin inhibited internalisation of Tz and prevented crosslinking from 
enhancing Tz endocytosis. B) SKBR3 cells were, in the continuous presence of 5 µM CytD or diluent control, either untreated (control) or incubated with Tz diluent control 
30 min followed by SA alone for 1 hr, Tz alone for 30 min (+ 1 hr SA diluent control), or Tz for 30 min followed by SA for 1 hr (Tz+SA). C) Band intensities were quantified using 
ImageJ software. Mean from 3 independent experiments is shown, error bars represent SE, *p≤0.05, **p≤0.01, ***p≤0.001. Data show that disruption of filamentous actin 
prevented crosslinking-induced downregulation of HER2 and restricted ERK activation. 
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targeting HER2: an approach that has been directly 
and indirectly attempted with diverse nanomedicines 
including nanoparticles, dendrimers and therapeutic 
antibodies (18, 23, 24).  
The endocytosis resistance of HER2 is well 
documented (6) and in line with this we observed 
relatively slow receptor downregulation in response 
to Tz treatment. It was 7 hr before HER2 was signifi-
cantly depleted by Tz ± crosslinking. This represents a 
relatively low rate of endocytic downregulation 
compared with a prototypical receptor such as ligand- 
bound EGFR where the majority of the receptor 
degrades within 1 hr of epidermal growth factor 
(EGF) stimulation (38). There are conflicting reports in 
the literature about the ability of Tz to drive lysosomal 
degradation of HER2 (6) but our data adds to the 
body of evidence that the antibody can induce 
receptor downregulation. We show, in line with our 
previous findings (16) and with the literature (19), that 
crosslinking of HER2 at the plasma membrane can 
enhance the endocytic degradation of HER2 in 
Tz-sensitive breast cancer cell lines. We show here for 
the first time that ERK activation is a product of 
HER2-crosslinking but is not required for 
 
 
Figure 6. Crosslinking does not enhance lysosomal targeting of Tz in a Tz-resistant breast cancer cell line and consequently does not induce HER2 
downregulation or ERK activation. BT474 clone 5 (acquired Tz resistant) cells were either untreated (control) or incubated with Tz diluent control 30 min followed by SA 
alone for 1 hr, Tz alone for 30 min (+ 1 hr SA diluent control), or Tz for 30 min followed by SA for 1 hr (Tz+SA) then a 6 hr chase in CIM. For microscopy experiments lysosomes 
were labelled by dextran pulse-chase prior to antibody treatment. A) Confocal microscopy showing no significant difference in colocalisation between Tz and lysosomes ± SA 
crosslinking. B) Western blotting was performed for HER2, P-ERK and total ERK (representative blot shown) and C) band intensities were quantified using ImageJ software. Mean 
from 3 independent experiments is shown, error bars represent SE, ****p≤0.0001. Data revealed no difference in HER2 downregulation or ERK activation in Tz-resistant 
cells treated with Tz alone or Tz+SA crosslinking. 
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internalisation. A previous study using polyclonal 
antibodies against HER2 showed higher levels of 
P-ERK but the effect was not explored in the report 
(20). Thus, ERK activation appears to be a specific and 
reproducible consequence of HER2 crosslinking, 
independently of the approach used. It may in fact be 
a broader consequence of plasma-membrane protein 
crosslinking as it has been reported in response to a 
diverse range of crosslinked targets including 
integrins, and EGFR (39, 40). 
 From a clinical perspective hyperactivation of 
ERK may be considered undesirable as it has been 
linked to the development of Tz-induced toxicity. 
Phosphorylation of ERK has been documented in 
cardiomyocytes following Tz treatment, this inhibited 
autophagy and stimulated reactive oxygen species 
(ROS) production leading to cardiomyopathy (41). 
Importantly, ERK hyperactivation is also a known Tz 
resistance mechanism (42). Since we have previously 
(16), and here, demonstrated HER2 recovery within 
48 hr of Tz or crosslinking treatment it may be that the 
ERK activation is a compensatory signal to the cell to 
produce more HER2 in response to receptor 
depletion. This could occur via stimulation of the ETS 
transcription factor ER81 which is known to be 
activated by ERK and to regulate HER2 promoter 
activity (43). The recovery of HER2 represents a 
limitation of a crosslinking based approach as a 
monotherapy for driving HER2 downregulation. On 
the other hand, HER2 replenishment at the plasma 
membrane is potentially beneficial for enhancing 
ADC treatment as it would enable retargeting should 
a cell survive an initial ADC dose.  
The difference between cell lines after 
crosslinking in the proportion of Tyr-1248 P-HER2 
relative to total HER2 may relate to differences in the 
levels of other ErbB receptors and in HER2 
dimerisation profile. Such differences are known 
between SKBR3 and BT474 cells and have been 
reported to modulate Tz sensitivity (44). A number of 
possible scenarios could account for the reduced 
Tyr-1248 P-HER2 in SKBR3 cells, it may be that 
crosslinking inhibits HER2 activation at this residue, 
or that crosslinking promotes phosphatase activity 
against Tyr-1248 P-HER2. Alternatively, it may be that 
a greater proportion of Tyr-1248 P-HER2 is degraded 
in crosslinking treated cells compared with Tz alone. 
The finding might be considered particularly 
surprising given that phosphorylation of this tyrosine 
residue is known to couple HER2 to the 
Ras/Raf/MEK/ERK pathway (45), which we show 
here to be more, not less, activated by crosslinking. 
Phosphorylation of HER2 and ERK have been shown 
to be reduced with longer term Tz exposure (>24 hr) 
following an initial spike in activation with short term 
(1 hr) exposure (46). We can speculate that 
crosslinking may alter the kinetics of the Tz response 
in breast cancer cells, altering the magnitude and 
duration of the HER2 and ERK signals induced by the 
antibody alone. For ERK in particular this may have 
significant cellular implications as the size and 
duration of this protein’s activation are known to be 
critical determinants of signalling outcome (47). 
Irrespective of mechanism, reduced Tyr-1248 P-HER2 
levels supports the therapeutic potential of 
crosslinking, as phosphorylation of this residue has 
been linked to poor clinical outcome (48).  
We show here for the first time that HER3 is 
concomitantly downregulated with HER2 in response 
to crosslinking while EGFR levels are unchanged. It 
can, in part, be explained by HER2’s documented 
propensity to preferentially dimerise with HER3 (over 
other ErbB receptors) (12). Tz alone was previously 
shown to induce HER3 downregulation though only 
to a limited degree and over a three day period of 
continuous incubation (45). Here we demonstrate 
significant potentiation of HER3 downregulation by 
Tz crosslinking. We suggest this may be the result of 
crosslinked Tz being able to induce more widespread 
downregulation of HER3:HER2 heterodimers than 
can be achieved with Tz alone. This we base on the 
principle that Tz alone can only induce large-scale 
crosslinking of HER2 homodimers whereas the 
multivalent SA enables extensive oligomerisation of 
HER2 homodimers and HER2:HER3 heterodimers 
(Supplementary figure S7). Interestingly, targeting of 
HER3 with polyclonal antibodies has recently been 
shown to induce downregulation of HER3 and HER2 
(49) which, with our findings, suggests that 
crosslinking of either receptor allows concomitant 
targeting its dimerisation partner. The HER2:HER3 
heterodimer is a potent, constitutive inducer of 
oncogenic signalling and HER3 transcriptional 
upregulation is a known mechanism of resistance to 
HER2 inhibition (50). Breast cancers driven by HER2 
homodimers have been shown to be more sensitive to 
Tz (27) so crosslinking may offer a therapeutic 
advantage by enabling targeting of tumours driven by 
HER2:HER3 heterodimers. 
Our siRNA depletion studies showing partial 
inhibition of crosslinking enhanced Tz endocytosis in 
CME and CIE impaired cells, indicate that multiple 
endocytic pathways are involved in the process. This 
provides a therapeutic advantage as degeneracy of 
uptake mechanism potentially subverts resistance 
mechanisms involving perturbations of specific 
endocytic pathways such as those documented for Tz 
and T-DM1 resistance (31, 51). The involvement of 
multiple endocytic pathways and of actin to HER2 
endocytosis has been suggested previously using 
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chemical inhibitors and dynamin mutants to impede 
uptake of multiple HER-targeted antibodies (21). Our 
data, obtained with more-specific siRNAs, more 
clearly implicate caveolin and flotillin in the processes 
governing crosslinking-enhanced Tz:HER2 endocyto-
sis. 
Actin filaments (stress fibres) have been shown 
to attach at sites of clustered plasma membrane 
receptors, including those crosslinked by antibody 
binding, and this is thought to facilitate endocytosis 
(52). Actin inhibition, here and in the literature for a 
HER2-targeted antibody mixture (21), has been 
shown to inhibit antibody:receptor internalisation. 
This has been interpreted as macropinocytosis being 
the primary uptake mechanism of Tz. However, the 
specificity of CytD for macropinocytosis is 
questionable owing to actin’s varied role in receptor 
endocytosis (53). We therefore favour the description 
of our findings as evidence of actin dependency rather 
than of macropinocytosis. We suggest that actin may 
play a role in the changes in plasma membrane 
organisation/structure, seen with Tz and exacerbated 
by crosslinking. Plasma membrane remodelling, 
including actin reorganisation, has been reported for 
antibodies targeting EGFR (54). However, for these 
antibodies uptake was shown to occur via circular 
dorsal ruffles and the experiments were conducted 
under serum-starvation conditions. Crucially, our 
experiments are conducted in full-serum which better 
reflects physiological conditions and provides greater 
confidence for in vitro – in vivo translation. Actin 
reorganisation is a complex, highly regulated process 
so there may be further mechanistic insight to be 
gained from future studies dissecting critical actin 
regulators such as Rho, Rac and PAK1 (55). 
Our SEM images show the microvilli-rich 
plasma membrane of HER2 overexpressing cells in 
very high detail. Previous studies have demonstrated 
HER2 enrichment in membrane protrusions (7) and 
this work was extended by others who showed the 
microvilli were directly generated by HER2 
overexpression and clustering (34). The later study 
showed by total internal reflection microscopy 
(TIRFM) that antibody binding to HER2 can deform 
microvilli, an effect our SEM work shows 
topographically and we show for the first time that 
plasma membrane remodelling can be dramatically 
enhanced by crosslinking. Distortion of the HER2 
extracellular domain by DARPins has been shown to 
alter receptor activation and signalling (56) and we 
hypothesise that crosslinking by Tz at the extra-
cellular juxtamembrane domain, may induce similar 
changes in HER2 structure and organisation. This 
would directly couple the morphological changes in 
HER2-containing microvilli to the alterations in HER2 
activity and downstream signalling. 
Ado-trastuzumab emtansine (T-DM1/Kadcyla) 
is an ADC that was developed to improve Tz efficacy 
by using it to deliver the cytotoxic emtansine into 
HER2-overexpressing cells(57). However, T-DM1 has 
a fairly poor cost:benefit profile compared with Tz 
alone and is only used in patients who have 
developed Tz resistance. HER2’s endocytic deficiency 
significantly limits the efficacy of standard ADC 
approaches as lysosomal delivery is required for 
intracellular cytotoxic release. Our discovery that 
crosslinking was unable to enhance Tz internalisation 
and HER2 downregulation in a cell model of 
Tz-resistance provides invaluable information with 
respect to understanding the limitations of the 
approach in future therapies. This is particularly 
pertinent given the increasing evidence of resistance 
to T-DM1 developing (51, 57) and in the current trend 
towards crosslinking in HER2 targeting. In a study 
using a biparatopic antibody targeting distinct HER2 
epitopes to crosslink and downregulate the receptor, 
the construct was shown to have activity against cell 
models of de novo Tz resistance (18). Taken with our 
findings in an acquired Tz-resistant cell line the data 
might be pointing to critical differences in the 
mechanisms driving primary and secondary 
resistance and this may have implications for therapy 
selection (personalised medicine). The results may 
simply reflect a difference in the crosslinking strategy 
itself e.g. single agent (biparatopic antibody) versus 
sequential SA-mediated crosslinking. Further 
experimentation, beyond the scope of this study, is 
required to determine to what extent the sensitivity of 
a HER2-overexpressing cell line to a crosslinking 
strategy depends on a particular resistance 
mechanism or cell type. The role of endocytosis in Tz 
sensitivity and in HER2 crosslinking susceptibility 
should particularly be explored. 
Conclusions 
Our studies have demonstrated that crosslinking 
significantly enhances the endocytosis of Tz in 
HER2-overexpressing breast cancer and induces 
effects of potential therapeutic benefit including 
promotion of HER2 and HER3 downregulation and 
alteration of HER2 activation and signalling. The 
improved endocytic capacity and lysosomal targeting 
of crosslinked HER2 would theoretically translate to 
T-DM1, improving the efficacy of this therapeutic 
currently limited in clinical use. We have revealed 
that a cell model of acquired Tz-resistance is not 
responsive to crosslinking with respects to HER2 
endocytosis, signalling and downregulation. This has 
implications for existing therapeutic approaches 
based on antibody crosslinking (e.g. combined Tz and 
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pertuzumab) as well as future strategies seeking to 
tackle Tz-resistance. Overall, our results will aid the 
design of future Tz-based therapeutics with improved 
capacity for HER2 downregulation and cytotoxic 
delivery. Our findings provide a new perspective on 
the crosslinking-based receptor targeting in breast 
cancer. They may also have implications for the whole 
remit of antibody and crosslinking-based receptor 
targeting in cancer. 
Abbreviations  
ADC: Antibody drug conjugate; AP2M1: 
Adaptor protein complex 2 subunit mu; CAV1: 
Caveolin 1; CIM: Complete imaging media; CytD: 
Cytochalasin D; DMEM: Dulbecco's modified eagle 
medium; EHT: Extra high tension voltage level; EGF: 
Epidermal growth factor; EGFR: Epidermal growth 
factor receptor; ERK: Extracellular signal related 
kinase; HDMS: Hexamethyldisilazane; HER2/3: 
Human epidermal growth factor receptor 2/3; 
FLOT1: Flotillin 1; PBS: Phosphate buffered saline; 
PVDF: Polyvinylidene fluoride; NA: Numerical 
aperture; SA: Streptavidin; SEM: Scanning electron 
microscopy; T-DM1: Ado-trastuzumab emtansine; 
TIRFM: Total internal reflection microscopy; Tz: 
Trastuzumab; Tz-bi-647: Biotinylated trastuzumab 
conjugated to Alexa647. 
Supplementary Material  
Supplementary methods, figures, and table.  
http://www.jcancer.org/v11p3288s1.pdf  
Acknowledgements 
The authors are grateful to Professor Peter 
Barrett-Lee (Velindre NHS Trust Cancer Centre, 
Cardiff, UK) for his expertise and for proof-reading 
the manuscript. We wish to thank Cancer Research 
Wales and the Cardiff University Wellcome Trust 
ISSF3 award for suppling the funding for this study. 
Competing Interests 
The authors have declared that no competing 
interest exists. 
References 
1. Moasser MM. The oncogene HER2: its signaling and transforming functions 
and its role in human cancer pathogenesis. Oncogene. 2007;26(45):6469. 
2. Cronin KA, Harlan LC, Dodd KW, Abrams JS, Ballard-Barbash R. 
Population-based estimate of the prevalence of HER-2 positive breast cancer 
tumors for early stage patients in the US. Cancer investigation. 
2010;28(9):963-8. 
3. Rakha EA, Pinder SE, Bartlett JM, Ibrahim M, Starczynski J, Carder PJ, et al. 
Updated UK Recommendations for HER2 assessment in breast cancer. Journal 
of clinical pathology. 2015;68(2):93-9. 
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human 
breast cancer: correlation of relapse and survival with amplification of the 
HER-2/neu oncogene. Science. 1987;235(4785):177-82. 
5. Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in 
breast cancer. Oncogene. 2000;19(53):6102. 
6. Bertelsen V, Stang E. The mysterious ways of ErbB2/HER2 trafficking. 
Membranes. 2014;4(3):424-46. 
7. Hommelgaard AM, Lerdrup M, van Deurs B. Association with membrane 
protrusions makes ErbB2 an internalization-resistant receptor. Molecular 
biology of the cell. 2004;15(4):1557-67. 
8. Cortese K, Howes MT, Lundmark R, Tagliatti E, Bagnato P, Petrelli A, et al. 
The HSP90 inhibitor geldanamycin perturbs endosomal structure and drives 
recycling ErbB2 and transferrin to modified MVBs/lysosomal compartments. 
Molecular biology of the cell. 2013;24(2):129-44. 
9. Austin CD, De Mazière AM, Pisacane PI, van Dijk SM, Eigenbrot C, 
Sliwkowski MX, et al. Endocytosis and sorting of ErbB2 and the site of action 
of cancer therapeutics trastuzumab and geldanamycin. Molecular biology of 
the cell. 2004;15(12):5268-82. 
10. Hendriks BS, Opresko LK, Wiley HS, Lauffenburger D. Coregulation of 
Epidermal Growth Factor Receptor/Human Epidermal Growth Factor 
Receptor 2 (HER2) Levels and Locations Quantitative Analysis of HER2 
Overexpression Effects. Cancer research. 2003;63(5):1130-7. 
11. Shen F, Lin Q, Childress C, Yang W. Identification of the domain in ErbB2 that 
restricts ligand-induced degradation. Cellular signalling. 2008;20(4):779-86. 
12. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, et al. A 
hierarchical network of interreceptor interactions determines signal 
transduction by Neu differentiation factor/neuregulin and epidermal growth 
factor. Molecular and cellular biology. 1996;16(10):5276-87. 
13. Haslekås C, Breen K, Pedersen KW, Johannessen LE, Stang E, Madshus IH. 
The inhibitory effect of ErbB2 on epidermal growth factor-induced formation 
of clathrin-coated pits correlates with retention of epidermal growth factor 
receptor-ErbB2 oligomeric complexes at the plasma membrane. Molecular 
biology of the cell. 2005;16(12):5832-42. 
14. Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM, et al. 
Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances 
tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis 
in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer 
research. 2001;61(12):4892-900. 
15. Nahta R, Yu D, Hung M-C, Hortobagyi GN, Esteva FJ. Mechanisms of disease: 
understanding resistance to HER2-targeted therapy in human breast cancer. 
Nature Reviews Clinical Oncology. 2006;3(5):269. 
16. Moody PR, Sayers EJ, Magnusson JP, Alexander C, Borri P, Watson P, et al. 
Receptor crosslinking: a general method to trigger internalization and 
lysosomal targeting of therapeutic receptor: ligand complexes. Molecular 
Therapy. 2015;23(12):1888-98. 
17. Ekblad T, Tolmachev V, Orlova A, Lendel C, Abrahmsén L, Karlström AE. 
Synthesis and chemoselective intramolecular crosslinking of a HER2‐binding 
affibody. Peptide Science. 2009;92(2):116-23. 
18. Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, et al. A 
biparatopic HER2-targeting antibody-drug conjugate induces tumor 
regression in primary models refractory to or ineligible for HER2-targeted 
therapy. Cancer cell. 2016;29(1):117-29. 
19. Zhu W, Okollie B, Artemov D. Controlled internalization of Her-2/neu 
receptors by cross-linking for targeted delivery. Cancer biology & therapy. 
2007;6(12):1960-6. 
20. Ren X-R, Wei J, Lei G, Wang J, Lu J, Xia W, et al. Polyclonal HER2-specific 
antibodies induced by vaccination mediate receptor internalization and 
degradation in tumor cells. Breast Cancer Research. 2012;14(3):R89. 
21. Szymanska M, Fosdahl AM, Nikolaysen F, Pedersen MW, Grandal MM, Stang 
E, et al. A combination of two antibodies recognizing non‐overlapping 
epitopes of HER2 induces kinase activity‐dependent internalization of HER2. 
Journal of cellular and molecular medicine. 2016;20(10):1999-2010. 
22. Mahlknecht G, Maron R, Mancini M, Schechter B, Sela M, Yarden Y. Aptamer 
to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic 
growth. Proceedings of the National Academy of Sciences. 
2013;110(20):8170-5. 
23. Lee AL, Wang Y, Cheng HY, Pervaiz S, Yang YY. The co-delivery of paclitaxel 
and Herceptin using cationic micellar nanoparticles. Biomaterials. 
2009;30(5):919-27. 
24. Miyano T, Wijagkanalan W, Kawakami S, Yamashita F, Hashida M. Anionic 
Amino Acid Dendrimer− Trastuzumab Conjugates for Specific Internalization 
in HER2-Positive Cancer Cells. Molecular pharmaceutics. 2010;7(4):1318-27. 
25. Humphries IV WH, Szymanski CJ, Payne CK. Endo-lysosomal vesicles 
positive for Rab7 and LAMP1 are terminal vesicles for the transport of 
dextran. PloS one. 2011;6(10):e26626. 
26. He L, Sayers E, Watson P, Jones A. Contrasting roles for actin in the cellular 
uptake of cell penetrating peptide conjugates. Scientific reports. 2018;8. 
27. Ghosh R, Narasanna A, Wang SE, Liu S, Chakrabarty A, Balko JM, et al. 
Trastuzumab has preferential activity against breast cancers driven by HER2 
homodimers. Cancer research. 2011;71(5):1871-82. 
28. Gijsen M, King P, Perera T, Parker PJ, Harris AL, Larijani B, et al. HER2 
phosphorylation is maintained by a PKB negative feedback loop in response to 
anti-HER2 herceptin in breast cancer. PLoS biology. 2010;8(12):e1000563. 
29. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, 
resistance and future perspectives in HER2-overexpressing breast cancer. 
Annals of oncology. 2007;18(6):977-84. 
30. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. 
Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is 
required for antibody-mediated effects on p27, cyclin D1, and antitumor 
action. Cancer research. 2002;62(14):4132-41. 
 Journal of Cancer 2020, Vol. 11 
 
http://www.jcancer.org 
3302 
31. Sekhar SC, Kasai T, Satoh A, Shigehiro T, Mizutani A, Murakami H, et al. 
Identification of caveolin-1 as a potential causative factor in the generation of 
trastuzumab resistance in breast cancer cells. Journal of Cancer. 2013;4(5):391. 
32. Asp N, Pust S, Sandvig K. Flotillin depletion affects ErbB protein levels in 
different human breast cancer cells. Biochimica et Biophysica Acta 
(BBA)-Molecular Cell Research. 2014;1843(9):1987-96. 
33. Al Soraj M, He L, Peynshaert K, Cousaert J, Vercauteren D, Braeckmans K, et 
al. siRNA and pharmacological inhibition of endocytic pathways to 
characterize the differential role of macropinocytosis and the actin 
cytoskeleton on cellular uptake of dextran and cationic cell penetrating 
peptides octaarginine (R8) and HIV-Tat. Journal of Controlled Release. 
2012;161(1):132-41. 
34. Chung I, Reichelt M, Shao L, Akita RW, Koeppen H, Rangell L, et al. High 
cell-surface density of HER2 deforms cell membranes. Nature 
communications. 2016;7:12742. 
35. McMahon HT, Gallop JL. Membrane curvature and mechanisms of dynamic 
cell membrane remodelling. Nature. 2005;438(7068):590. 
36. Ben-Kasus T, Schechter B, Lavi S, Yarden Y, Sela M. Persistent elimination of 
ErbB-2/HER2-overexpressing tumors using combinations of monoclonal 
antibodies: relevance of receptor endocytosis. Proceedings of the National 
Academy of Sciences. 2009;106(9):3294-9. 
37. Kute T, Lack CM, Willingham M, Bishwokama B, Williams H, Barrett K, et al. 
Development of Herceptin resistance in breast cancer cells. Cytometry Part A. 
2004;57(2):86-93. 
38. Wymant JM, Hiscox S, Westwell AD, Urbé S, Clague MJ, Jones AT. The Role of 
BCA2 in the Endocytic Trafficking of EGFR and Significance as a Prognostic 
Biomarker in Cancer. Journal of Cancer. 2016;7(15):2388. 
39. Miyamoto S, Teramoto H, Gutkind JS, Yamada KM. Integrins can collaborate 
with growth factors for phosphorylation of receptor tyrosine kinases and MAP 
kinase activation: roles of integrin aggregation and occupancy of receptors. 
The Journal of cell biology. 1996;135(6):1633-42. 
40. Sun X, Dusserre-Bresson F, Baker B, Zhang A, Xu P, Fibbe C, et al. Probing 
homodimer formation of epidermal growth factor receptor by selective 
crosslinking. European journal of medicinal chemistry. 2014;88:34-41. 
41. Mohan N, Shen Y, Endo Y, ElZarrad MK, Wu WJ. Trastuzumab, but not 
pertuzumab, dysregulates HER2 signaling to mediate inhibition of autophagy 
and increase in reactive oxygen species production in human cardiomyocytes. 
Molecular cancer therapeutics. 2016;15(6):1321-31. 
42. Kim J-W, Kim DK, Min A, Lee K-H, Nam H-J, Kim JH, et al. Amphiregulin 
confers trastuzumab resistance via AKT and ERK activation in HER2-positive 
breast cancer. Journal of cancer research and clinical oncology. 
2016;142(1):157-65. 
43. Bosc DG, Janknecht R. Regulation of Her2/neu promoter activity by the ETS 
transcription factor, ER81. Journal of cellular biochemistry. 2002;86(1):174-83. 
44. Diermeier S, Horváth G, Knuechel-Clarke R, Hofstaedter F, Szöllősi J, 
Brockhoff G. Epidermal growth factor receptor coexpression modulates 
susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via 
specific erbB-receptor interaction and activation. Experimental cell research. 
2005;304(2):604-19. 
45. Dokmanovic M, Wu Y, Shen Y, Chen J, Hirsch DS, Wu WJ. 
Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 
receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 
degradation to mediate cell growth inhibition. Cancer biology & therapy. 
2014;15(8):1029-41. 
46. Menendez JA, Mehmi I, Lupu R. Trastuzumab in Combination With 
Heregulin-Activated Her-2 (erb B-2) Triggers a Receptor-Enhanced 
Chemosensitivity Effect in the Absence of Her-2 Overexpression. Journal of 
clinical oncology. 2006;24(23):3735-46. 
47. Ebisuya M, Kondoh K, Nishida E. The duration, magnitude and 
compartmentalization of ERK MAP kinase activity: mechanisms for providing 
signaling specificity. Journal of cell science. 2005;118(14):2997-3002. 
48. Cicenas J, Urban P, Küng W, Vuaroqueaux V, Labuhn M, Wight E, et al. 
Phosphorylation of tyrosine 1248-ERBB2 measured by 
chemiluminescence-linked immunoassay is an independent predictor of poor 
prognosis in primary breast cancer patients. European Journal of Cancer. 
2006;42(5):636-45. 
49. Osada T, Hartman ZC, Wei J, Lei G, Hobeika AC, Gwin WR, et al. 
Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) 
antibodies induced by HER3 vaccines have multiple mechanisms of antitumor 
activity against therapy resistant and triple negative breast cancers. Breast 
Cancer Research. 2018;20(1):90. 
50. Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, 
Chakrabarty A, et al. Transcriptional and posttranslational up-regulation of 
HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. 
Proceedings of the National Academy of Sciences. 2011;108(12):5021-6. 
51. Sung M, Tan X, Lu B, Golas J, Hosselet C, Wang F, et al. Caveolae-mediated 
endocytosis as a novel mechanism of resistance to trastuzumab emtansine 
(T-DM1). Molecular cancer therapeutics. 2018;17(1):243-53. 
52. Ash J, Louvard D, Singer S. Antibody-induced linkages of plasma membrane 
proteins to intracellular actomyosin-containing filaments in cultured 
fibroblasts. Proceedings of the National Academy of Sciences. 
1977;74(12):5584-8. 
53. Fujimoto LM, Roth R, Heuser JE, Schmid SL. Actin assembly plays a variable, 
but not obligatory role in receptor‐mediated endocytosis. Traffic. 
2000;1(2):161-71. 
54. Orth JD, Krueger EW, Weller SG, McNiven MA. A novel endocytic mechanism 
of epidermal growth factor receptor sequestration and internalization. Cancer 
research. 2006;66(7):3603. 
55. Croise P, Estay-Ahumada C, Gasman S, Ory S. Rho GTPases, 
phosphoinositides, and actin: a tripartite framework for efficient vesicular 
trafficking. Small GTPases. 2014;5:e29469. 
56. Jost C, Schilling J, Tamaskovic R, Schwill M, Honegger A, Plückthun A. 
Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer 
cells via binding to the extracellular domain of HER2. Structure. 
2013;21(11):1979-91. 
57. Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action 
and drug resistance. Breast cancer research. 2014;16(2):209. 
58. Ghosh R, Narasanna A, Wang SE, Liu S, Chakrabarty A, Balko JM, 
González-Angulo AM, Mills GB, Penuel E, Winslow J, Sperinde J, Dua R, 
Pidaparthi S, Mukherjee A, Leitzel K, Kostler WJ, Lipton A, Bates M and 
Arteaga CL. Trastuzumab has preferential activity against breast cancers 
driven by HER2 homodimers. Cancer Research 2011;71(5):1871–82. 
 
